HER2 e carcinoma gastrico

Allgayer H et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with
the expression of tumor-associated protease systems. J Clin Oncol. 2000;18(11):2201-9.
American Joint Committee on Cancer 2010. AJCC Cancer TNM Staging Manual, /a edizione, gennaio 2010. Disponibili su Associazione Italiana Registri Tumori, 2010 Bang YJ et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009; 27:Abstract 4556. Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial; Lancet 2010;376:687-697. Blot W et al, Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991 Mar 13;265(10):1287-9. Coussens L et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985:1132-1139. Cortes-Funes H, et al.: Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007, 25(18):s4613. Cunningham D, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36–46. Dank M, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19:1450–1457). Dawood S. et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28: 92-98. Devesa SS et al, Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998 Nov 15;83(10):2049-53. Di Fiore PP et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells; Science. 1987:178-182. Egamberdiev DM et al: Our experience in the use of trastuzumab in patients with advanced stomach Ferlay J et al, Estimates of the cancer incidence and mortality in Europe in 2006, Annals of Oncology 18: 581–592, 2007 Fujimoto-Ouchi K et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2007;59:795–805. Gravalos C & Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-1529. Hendriks BS et al. Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res. 2003. 63:1130-7. Hofmann M et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52(7):797-805. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1994;1198:165-84. Kang Y.K, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20:666–673. Kim SY et al, Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol. 2008 Jan;32(1):89-95 Lordick et al. HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. Eur J Cancer 2007;5(4):271. (Abstr 3541). Meza-Junco J et al, Critical appraisal of trastuzumab in treatment of advanced stomach cancer, Meza-Junco J, Caancer Manag Research 2011; 3:57-64 Mitzutani t et al, Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer. 1993 Oct 1;72(7):2083-8. Murad AM et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37–41. Okines A et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v50-4. Nicholas, G. et al. Early results of a trial of trastuzumab, cisplatin, and docetaxel (TCD) for the treatment of metastatic gastric cancer overexpressing HER-2 [abstract]. Ann. Oncol. 17 (Suppl. 9), a1105P (2006). Park DI, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51:1371–1379. doi: 10.1007/s10620-005-9057-1. Parkin DM et al. Global cancer statistics, 2002; CA Cancer J Clin. 2005;55(2):74-108. Pera M et al, Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993 Feb;104(2):510-3. Satoh T, et al.: Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. In 2010 Gastrointestinal Cancers Symposium; Jan 22—24, 2010; Orlando, FL, USA; abstr 7. Semba K et al. A v-erbB related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A. 1986;82(19):6497–501. Tanner M et al, Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005 Feb;16(2):273-8. Uchino S et al, Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer. 1993 Dec 1;72(11):3179-84. Van Cutsem E et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 2006;24:4991–7. Van Cutsem E, et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) J Clin Oncol 2009; 27(18S):Abstract 4509. Vanhoefer U et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 2000;18:2648–57. Yang-Feng TL et al. The terminal deoxynucleotidyltransferase gene is located on human chromosome 10 (10q23----q24) and on mouse chromosome 19. Cytogenetics and Cell Genetics, 1986; 43(3-4), 121-126. Yonemura t et al, Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer. 1991 Jun 1;67(11):2914-8. Zhang XL, et al . Comparative study on overexpression of her2/neu and her3 in gastric cancer. World J Surg. 2009;33:2112–2118

Source: http://effetti.ecmcampus.it/ef09/upload/all/Modulo01_10.pdf


Iliotibial band friction syndrome—A systematic reviewHealth Rehabilitation Research Centre, Division of Rehabilitation and Occupation Studies, Faculty of Health & Environmental Sciences, AUTUniversity, Private Bag 92006, Auckland, New ZealandReceived 19 October 2004; received in revised form 19 July 2006; accepted 30 August 2006Iliotibial band friction syndrome (ITBFS) is a common


Dept. of Stat. Methods, University of L´ e-mail : [email protected] celebrated Kaplan-Meter estimator (KME) suffers from a disadvantage:it may happen that estimated probabilities of survival for two different times t 1and t 2 are equal each to other while t 1 and t 2 differ substantially. We proposea smoothinq of KME in such a way that the resulting estimator is a strictlydec

Copyright © 2009-2018 Drugs Today